Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
Michael W. Shaw, Rebecca Garten, Larisa V. Gubareva, Alexander Klimov, Margaret Okomo-Adhiambo, Vasiliy P. Mishin, Tiffany G. Sheu, Varough M. Deyde, Ha T. Nguyen, A. Angelica Trujillo, Alicia M. Fry, Katrina Sleeman
Publikováno v:
Antiviral Therapy. 15:1151-1159
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. Me
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:3671-3677
The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the treatment and prophylaxis of 2009 pandemic influenza A (H1N1) virus infections. The proven potential of these viruses to acquire NA
Autor:
Rebecca Garten, Ha T. Nguyen, Tiffany G. Sheu, Varough M. Deyde, Alexander Klimov, Katrina Sleeman, Margaret Okomo-Adhiambo, Xiyan Xu, Michael W. Shaw, Larisa V. Gubareva
Publikováno v:
Antiviral Research. 85:381-388
The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-20
Autor:
Novikov Dv, Larisa V. Gubareva, Frederick G. Hayden, Marina S. Nedyalkova, Erich Hoffmann, K. Gopal Murti
Publikováno v:
Journal of General Virology. 83:2683-2692
Both influenza A virus surface glycoproteins, the haemagglutinin (HA) and neuraminidase (NA), interact with neuraminic acid-containing receptors. The influenza virus A/Charlottesville/31/95 (H1N1) has shown a substantially reduced sensitivity to NA i
Publikováno v:
Antiviral Research. 53:47-61
We previously characterized influenza viruses whose selection in the presence of neuraminidase (NA) inhibitors resulted in a substituted residue (position 119, 152, 274, or 292) in the NA active center. To identify the most favorable conditions for d
Autor:
Margaret Okomo-Adhiambo, Larisa V. Gubareva, Katrina Sleeman, Zhu Guo, Ha T. Nguyen, Xiyan Xu, James Stevens, Hua Yang, Vasiliy P. Mishin, Marnie Levine, Daisuke Tamura
Publikováno v:
Antimicrobial agents and chemotherapy. 57(12)
Assessment of drug susceptibility has become an integral part of influenza virus surveillance. In this study, we describe the drug resistance profile of influenza A(H3N2) virus, A/Mississippi/05/2011, collected from a patient treated with oseltamivir
Autor:
Mikhail Matrosovich, Robert G. Webster, Richard C. Bethell, Malcolm K. Brenner, Larisa V. Gubareva
Publikováno v:
The Journal of Infectious Diseases. 178:1257-1262
Zanamivir, a neuraminidase inhibitor, has shown promise as a drug to control influenza. During prolonged treatment with zanamivir, a mutant virus was isolated from an immunocompromised child infected with influenza B virus. A hemagglutinin mutation (
Publikováno v:
Journal of Virology. 71:3385-3390
Here we report the isolation of influenza virus A/turkey/Minnesota/833/80 (H4N2) with a mutation at the catalytic residue of the neuraminidase (NA) active site, rendering it resistant to the novel NA inhibitor 4-guanidino-Neu5Ac2en (GG167). The resis
Publikováno v:
Journal of Virology. 70:1818-1827
The development of viral resistance to the neuraminidase (NA) inhibitor, 4-guanidino-Neu5Ac2en, of influenza viruses was studied by serial passage of A/Turkey/Minnesota/833/80 (H4N2) in Madin-Darby canine kidney cells in the presence of increasing co